{"id":18869,"date":"2021-09-24T05:17:11","date_gmt":"2021-09-24T09:17:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18869"},"modified":"2021-09-23T15:20:09","modified_gmt":"2021-09-23T19:20:09","slug":"6-drugmakers-referred-to-hhs-inspector-general-for-denying-340b-discounts","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18869","title":{"rendered":"6 drugmakers referred to HHS inspector general for denying 340B discounts"},"content":{"rendered":"<p>(By Maia Anderson for Becker&#8217;s Hospital Review)<\/p>\n<p>The HHS Health Resources &amp; Services Administration sent letters to six drugmakers Sept. 22 warning that they may face monetary penalties of $5,000 each for refusing to give 340B discounts to covered entities.\u00a0 Continue reading the article <a href=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/6-drugmakers-referred-to-hhs-inspector-general-for-denying-340b-discounts.html\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-9962\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General-300x74.jpg\" alt=\"\" width=\"300\" height=\"74\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General-300x74.jpg 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General.jpg 623w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Maia Anderson for Becker&#8217;s Hospital Review) The HHS Health Resources &amp; Services Administration sent letters to six drugmakers Sept.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,53,15],"tags":[],"class_list":["post-18869","post","type-post","status-publish","format-standard","hentry","category-dhs-oig","category-hhs","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18869"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18869\/revisions"}],"predecessor-version":[{"id":18870,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18869\/revisions\/18870"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}